E01P0028 Human Plasminogen Activator Inhibitor 1 ELISA kit
The Human Plasminogen Activator Inhibitor 1 ELISA kit can be used to identify samples from the human species. Plasminogen Activator Inhibitor 1 can also be called PAI 1, SERPINE1, PLANH1, Serpin Peptidase Inhibitor Clade E Member 1, Nexin,Plasminogen Activator Inhibitor Type 1 Serpin E1, Endothelial plasminogen activator inhibitor.
Product Information | |
Cat. No. | E01P0028 |
Product Name | Human Plasminogen Activator Inhibitor 1 ELISA kit |
Species | Human |
Product Size | 48 Tests / 96 Tests |
Concentration | 250-5000 pg/ml |
Sensitivity | 1.0 pg/ml |
Principal | Sandwich ELISA |
Sample Volume | 50 ul |
Sample Type | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate |
Assay Time | 90 minutes |
Platform | Microplate Reader |
Conjugate | HRP |
Detection Method | Colorimetric |
Storage | 2-8°C |
Kit Components | ||
MATERIALS | SPECIFICATION | QUANTITY |
MICROTITER PLATE | 96 wells | stripwell |
ENZYME CONJUGATE | 10.0 mL | 1 vial |
STANDARD A (0.5mL) | 0 pg/mL | 1 vial |
STANDARD B (0.5mL) | 250 pg/mL | 1 vial |
STANDARD C (0.5mL) | 500 pg/mL | 1 vial |
STANDARD D (0.5mL) | 1000 pg/mL | 1 vial |
STANDARD E (0.5mL) | 2500 pg/mL | 1 vial |
STANDARD F (0.5mL) | 5000 pg/mL | 1 vial |
SUBSTRATE A | 6 mL | 1 vial |
SUBSTRATE B | 6 mL | 1 vial |
STOP SOLUTION | 6 mL | 1 vial |
WASH SOLUTION (100 x) | 10 mL | 1 vial |
BALANCE SOLUTION | 3 mL | 1 vial |
Principle of the Assay |
PAI 1 ELISA kit applies the quantitative sandwich enzyme immunoassay technique. The microtiter plate has been pre-coated with a monoclonal antibody specific for PAI 1. Standards or samples are then added to the microtiter plate wells and PAI 1 if present, will bind to the antibody pre-coated wells. In order to quantitatively determine the amount of PAI 1 present in the sample, a standardized preparation of horseradish peroxidase (HRP)-conjugated polyclonal antibody, specific for PAI 1 are added to each well to “sandwich” the PAI 1 immobilized on the plate. The microtiter plate undergoes incubation, and then the wells are thoroughly washed to remove all unbound coPAI 1nents. Next, substrate solutions are added to each well. The enzyme (HRP) and substrate are allowed to react over a short incubation period. Only those wells that contain PAI 1 and enzyme-conjugated antibody will exhibit a change in color. The enzyme-substrate reaction is terminated by addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The PAI 1 concentration in each sample is interpolated from this standard curve. |
Coefficient of Variance | Intra Variation% ＜10% | |
Inter Variation% ＜12% | ||
Recovery | 95-102% | |
Linearity | Diluent Ratio | Range % |
1:2 | 93-105 | |
1:4 | 88-106 | |
1:8 | 86-108 | |
Specificity/Cross-reactivity | No significant cross-reactivity or interference between PAI 1 and analogues was observed. | |
E01P0028 has been referenced in the below publications：
Effects of Chushi Huayu Prescription on Endothelin-1(ET-1) and Plasminogen Activator Inhibitor-1 (PAI-1) of Hyperuricemia Patients.
RESEARCH OF SUBCLINICAL ATHEROSCLEROSIS IN TYPE 2 DIABETIC PATIENTS WITH METABOLIC SYNDROME.
Related Bluegene Biotech Products
BlueGene Biotech News
